Rima Acosta

Neutralization, effector function and immune imprinting of Omicron variants

Amin Addetia, Luca Piccoli, James Brett Case et al. · Nature · 2023 · 181 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten et al. · The Lancet HIV · 2019 · 165 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 143 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin, Edwin DeJesus, Paul E. Sax et al. · The Lancet HIV · 2020 · 136 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Paul E. Sax, Jürgen K. Rockstroh, Anne F. Luetkemeyer et al. · Clinical Infectious Diseases · 2020 · 112 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17